Group 1 - The core point of the news is that Maiwei Biotech's stock has experienced a decline of 5.01%, with a current price of 38.28 CNY per share and a total market capitalization of 15.297 billion CNY [1] - Maiwei Biotech, established on May 12, 2017, specializes in the research, production, and sales of therapeutic biological products, with 99.91% of its revenue coming from product sales [1] - The trading volume for Maiwei Biotech reached 288 million CNY, with a turnover rate of 3.63% [1] Group 2 - According to data, the Shenyuan Lingxin Fund holds a significant position in Maiwei Biotech, with the Shenyuan Lingxin Medical Pioneer Stock A fund (005433) owning 288,500 shares, representing 4.98% of the fund's net value [2] - The Shenyuan Lingxin Medical Pioneer Stock A fund has reported a floating loss of approximately 582,800 CNY today [2] - The fund has a total asset size of 1.05 billion CNY and has experienced a year-to-date return of 6.17%, ranking 2698 out of 5579 in its category [2]

Core Viewpoint - Maiwei Biotech (688062) is expected to continue incurring losses in 2025, with a projected net profit attributable to shareholders ranging from -900 million to -995 million yuan compared to the previous year [1] Financial Performance - The company anticipates a significant increase in revenue from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISC MEDICINE, INC. [1] - There is a notable growth in drug sales revenue compared to the same period last year [1] Cost and Investment - As commercialization expands, both operating costs and sales expenses are expected to rise correspondingly [1] - The company maintains a high level of research and development investment, with multiple innovative drugs in critical trial phases [1]

Core Viewpoint - Maiwei Biotech announced an expected narrowing of losses for the fiscal year 2025, projecting a net profit attributable to the parent company of between -900 million to -994.5 million yuan, compared to a loss of -1,043.92 million yuan in the previous year [2] Financial Performance - The company anticipates a net profit attributable to the parent company, excluding non-recurring gains and losses, to be between -905 million to -999.5 million yuan [2]

Core Viewpoint - Maiwei Biotech has announced a profit forecast for 2025, projecting a net loss attributable to shareholders of the parent company between 900 million to 995 million yuan [1] Financial Performance - The company expects a net loss attributable to shareholders after deducting non-recurring gains and losses to be between 905 million to 1 billion yuan [1]

Core Viewpoint - Maiwei Biotech (688062.SH) is expected to continue reporting a net loss attributable to shareholders in 2025, with projected losses ranging from -900 million to -994.5 million yuan [1] Financial Performance - The company's operating revenue is anticipated to increase significantly compared to the previous year, primarily due to substantial income recognized from licensing agreements with Qilu Pharmaceutical Co., Ltd. and DISCMEDICINE, INC., along with a notable rise in drug sales revenue [1] - The expected net profit attributable to shareholders, excluding non-recurring gains and losses, is projected to be between -905 million and -999.5 million yuan [1] Cost and Investment Factors - As commercialization expands, both operating costs and sales expenses are expected to rise correspondingly [1] - The company is maintaining a high level of research and development investment, with multiple innovative drugs currently in critical trial phases [1]

格隆汇1月23日丨迈威生物公告，预计2025年年度实现归属于母公司所有者的净利润与上年同期相比， 将继续亏损，实现归属于母公司所有者的净利润为亏损9亿元到亏损9.95亿元。预计归属于母公司所有 者扣除非经常性损益后的净利润为亏损9.05亿元到亏损9.99亿元。上年同期，公司归属于母公司所有者 的净利润为亏损10.44亿元，归属于母公司所有者的扣除非经常性损益的净利润为亏损10.7亿元。公司营 业收入较上年同期增加较多，主要原因是公司与齐鲁制药有限公司、DISC MEDICINE, INC.的授权许可 合同确认收入金额较大，同时药品销售收入较上年同期增长较多。 ...

一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 （二）业绩预告情况 （1）经财务部门初步测算，预计 2025 年年度实现归属于母公司所有者的净 利润与上年同期相比，将继续亏损，实现归属于母公司所有者的净利润为 -90,000.00 万元到-99,450.00 万元。 证券代码：688062 证券简称：迈威生物 公告编号：2026-003 迈威（上海）生物科技股份有限公司 2025 年年度业绩预告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （二）随着商业化进一步拓展增加，营业成本及销售费用相应增加。 （三）随着新药研发管线持续推进，多个创新药物处于关键试验研究阶段， 整体研发投入保持较高水平。 （2）预计归属于母公司所有者扣除非经常性损益后的净利润为-90,500.00 万元到-99,950.00 万元。 （三）本次业绩预告情况未经注册会计师审计。 二、上年同期经营业绩和财务状况 （一）利润总额：-104,747.15 万元。归属于母公司所有者的净利润： - ...

Group 1 - The chemical sector continues to rise, with the Chemical ETF (516020) showing a 0.31% increase as of January 23 [1] - Key stocks in the sector include Dongfang Shenghong, Weixing Chemical, and Hongda Co., which have all seen gains exceeding 4% [1] - The Chemical ETF has attracted significant investment, with a net subscription amount close to 1.2 billion yuan over the last five trading days [2] Group 2 - Recent petrochemical projects have been included in the key engineering project list for 2026, providing strong support for the industry [3] - The National Development and Reform Commission has allocated special bonds to support energy-saving and environmental protection initiatives [3] - The chemical industry is entering a strategic window, with high-cost overseas marginal capacity exiting and a restructuring of the global chemical order [3] Group 3 - Analysts are optimistic about the chemical sector's recovery, driven by changes in corporate strategies and market dynamics [3] - Key areas of focus for investment include MDI, petrochemicals, phosphate chemicals, PVC, and polyester bottle chips [3] - The Chemical ETF (516020) is recommended as an efficient way to gain exposure to the sector, tracking the CSI sub-industry index [3]

（编辑 丛可心） 证券日报网讯 1月21日，迈威生物发布公告称，公司第二届董事会第二十七次会议决议，继续使用不超 过8亿元暂时闲置募集资金进行现金管理，期限12个月，可滚动使用；截至2025年6月30日，募集资金净 额约33.03亿元，已投48.45%用于抗体产业化等项目，最近12个月现金管理单日最高投入约3.57亿元， 尚未收回本金3877.05万元。 ...

国泰海通证券股份有限公司 关于迈威（上海）生物科技股份有限公司 继续使用部分暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为迈 威（上海）生物科技股份有限公司（以下简称"迈威生物"、"公司"或"发行人"） 首次公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理 办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》等 有关法律法规和规范性文件的要求，就迈威生物继续使用暂时闲置募集资金进行 现金管理的事项进行了审慎核查，并发表如下核查意见： 一、投资情况概述 （一）投资目的 1、投资品种 为提高募集资金使用效率，在不影响募投项目开展、募集资金使用计划和保 证募集资金安全的前提下，公司及全资子公司拟继续利用部分暂时闲置募集资金 进行现金管理，提高募集资金使用效益、增加股东回报。 （二）投资金额 在保证不影响公司募集资金投资计划正常进行的前提下，公司及全资子公司 拟继续使用最高不超过人民币 8 亿元的暂时闲置募集资金进行现金管理，使用期 限自董事会审议通过之日起 12 个月内有效，在前述额度及使用期限范围内，资 金可以循环滚动使 ...